Aug 2026· Theoretical and Natural Science· 0 citations
TL;DR
This article systematically reviews the component design, structural engineering, preparation technologies, clinical applications, and future development directions of LNPs, aiming to provide theoretical support and practical guidance for vector development in the era of precision medicine.
Abstract
Lipid nanoparticles (LNPs), as a benchmark platform for non-viral vectors, have become a core technology for the delivery of nucleic acid drugs (mRNA, siRNA) and gene editing tools, owing to their excellent biocompatibility, structural designability, and broad payload compatibility. Their development spans over six decades, progressing from early liposomes to innovations in ionizable lipids and further to multifunctional targeted LNPs, gradually establishing a comprehensive technological system encompassing structural design, preparation techniques, functional regulation, and clinical translation. This article systematically reviews the component design, structural engineering, preparation technologies, clinical applications, and future development directions of LNPs, aiming to provide theoretical support and practical guidance for vector development in the era of precision medicine.
A structured translational roadmap is proposed that prioritizes biologically predictive design, fit-for-purpose safety assessment, scalable good manufacturing practice production, early regulatory alignment, and clinically meaningful benefit over unnecessary structural complexity.
Yi Li, Rui Luo, Yuxuan Li et al.· Biomedicine & pharmacotherap...· 1 citation
This review summarized the mainstream approaches for engineering EVs and elaborated on recent applications of functionalized EVs in relevant biomedical fields, and discussed current challenges and future perspectives regarding the large‐scale production, standardized characterization, and safety evaluation of engineere...
Zhouming Cheng, Wen-Hui Zhao, Min Wang et al.· iNew Medicine· 1 citation
The review gives a general description of drug delivery systems that are based on nanotechnology, with liposomes, polymeric nanoparticles, dendrimers, solid lipid nanoparticles, and metallic nanoparticles being the main examples of nanocarriers.
Shalini Tiwari, S. Kotnala, Rohinee Bhandari et al.· Trends in Biomaterials & Art...· 0 citations
The benefits and limitations associated with nanoparticle-based therapies, including safety concerns and regulatory challenges, are critically examined and future perspectives on the clinical translation and advancement of nanomedicine are highlighted.
A'laa F A Elsaid, Sara K. Ghodeif, N. El-Shenawy· Nano LIFE· 0 citations
This review discusses the recent developments of lipid nanodiscs for drug delivery, focusing on design strategies, functionalization methods, and key challenges for potential clinical translation.
Thirupathi Ravula, C. N. Obi, A. Ramamoorthy· Colloids and Surfaces B: Bio...· 0 citations
Future progress of dendrimers will be accelerated by more simplified and easily scalable synthetic processes, enhanced targeting to specific tissues and cells, as well as artificial intelligence-assisted design and optimization to posture dendrimers as a next-generation platform for nucleic acid delivery and precision...
Qianqian Ni, D. Tomalia, Jing Wu et al.· Nature Reviews Chemistry· 1 citation
Zero-knowledge proofs can verify computing results without rerunning workloads or exposing sensitive data. Magnetar helps bring them into the mainstream with support for standard programming languages, major speed gains, and quantum-resistant security. The post Proof-based general-purpose computing with Magnetar appeared first on Microsoft Research.
